Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Last trade$7.01
Day change-$0.33 (-4.50%)
Day range$6.93 – $7.32
Volume291,777
Market cap$379M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$379.47M
Price / earnings
15.92×
Price / book
2.59×
Price / sales
1.64×
EV / sales
1.46×
EV / EBITDA
9.3×
Profitability
Earnings per share
$0.46
Return on assets
11.75%
Return on equity
16.25%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
3.03×
Quick ratio
2.81×
Cash ratio
0.8×
Cash flow
Price / cash flow
8.24×
Price / free cash flow
8.25×
Free cash flow
$46M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PBYI, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$55.06M
$56.5M
$44.81M
$75.45M
$54.48M
$52.44M
$46.01M
$59.08M
Cost of revenue
$15.2M
$12.48M
$10.42M
$23.13M
$12.17M
$12.3M
$10.56M
$13.92M
Gross profit
$39.86M
$44.03M
$34.39M
$52.33M
$42.3M
$40.14M
$35.45M
$45.16M
Selling, general and administrative
$16.3M
$17.55M
$18.42M
$18.38M
$16.82M
$18.05M
$17.6M
$16.62M
Research and development
$18.28M
$18.9M
$19.8M
$16.84M
$15.91M
$15.45M
$13.86M
$15.17M
Total operating expenses
$34.58M
$36.44M
$38.22M
$35.22M
$32.73M
$33.5M
$31.47M
$31.79M
Operating income
$5.27M
$7.59M
-$3.83M
$17.11M
$9.57M
$6.64M
$3.98M
$13.37M
Interest expense
$0
-$180K
-$731K
-$1.12M
-$1.49M
-$1.84M
-$2.18M
-$2.62M
Income before taxes
$6.17M
$8.25M
-$3.43M
$17.11M
$9.24M
$6.17M
$3.27M
$12.24M
Income taxes
$216K
$56K
$326K
$3.67M
$399K
$310K
$293K
-$7.07M
Net income
$5.96M
$8.19M
-$3.75M
$13.44M
$8.84M
$5.86M
$2.97M
$19.31M
Net income attributable to common shareholders
$5.96M
$8.19M
-$3.75M
$13.44M
$8.84M
$5.86M
$2.97M
$19.31M
EBITDA
$7.73M
$10.1M
-$1.24M
$19.76M
$12.3M
$9.4M
$6.78M
$16.21M
Basic earnings per share
$0.12
$0.16
-$0.07
$0.27
$0.18
$0.12
$0.06
$0.39
Diluted earnings per share
$0.11
$0.16
-$0.07
$0.26
$0.17
$0.12
$0.06
$0.38
Recent news
Company coverage with links to the original publishers.
Puma Biotechnology reported Q3 2026 revenue of $55.1 million with three key developments: the company became debt-free after paying off its final loan to Athyrium, generic competition in China reduced royalty revenue by $2.1 million prompting lower full-year guidance, and interim trial data for alisertib supports advancement to phase III breast cancer studies. With $108.5 million in cash and growing U.S. NERLYNX demand, Puma is balancing core product commercialization with clinical expansion while maintaining positive net income.
Puma Biotech reported Q3 2026 earnings of $0.15 per share, beating consensus estimates of $0.11 by 36.36%, but revenues of $55.1 million missed expectations by 3.54%. The company has outperformed the market by 79.7% year-to-date. With mixed estimate revisions, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.
Adma Biologics reported Q3 2026 earnings of $0.22 per share, beating consensus estimates of $0.19, with revenues of $141.1 million slightly exceeding expectations. However, the stock has declined 39.1% year-to-date versus the S&P 500's 10.6% gain. The company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Zacks highlights four breast cancer drug stocks for Breast Cancer Awareness Month. AstraZeneca and Roche are established large-cap pharma companies with strong commercial portfolios and pipeline opportunities. Puma Biotechnology relies on Nerlynx sales with a mid-stage pipeline candidate. Olema Oncology is a clinical-stage company dependent on its lead candidate palazestrant's phase III trial results expected in Q1 2027.
Four pharmaceutical and biotech companies are positioned in the breast cancer treatment market with varying growth prospects. AstraZeneca and Roche leverage established drug portfolios with expanding indications, Puma Biotechnology focuses on Nerlynx sales growth, while Olema Oncology awaits pivotal clinical trial results for its lead candidate palazestrant expected in Q1 2027.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.